
Secukinumab has demonstrated significantly higher efficacy vs. etanercept and ustekinumab in patients with moderate to severe plaque psoriasis. We aimed to report 52 week results from a prespecified analysis of patients with active psoriatic arthritis having concomitant moderate to severe plaque psoriasis from the head to head EXCEED monotherapy study comparing secukinumab with adalimumab. Of the 853 patients [secukinumab (N = 426), adalimumab (N = 427)], 211 (24·7%) had concomitant moderate‐to‐severe psoriasis [secukinumab (N = 110, 25·8%), adalimumab (N = 101, 23·7%)]. Up to week 50, 5·5% of patients discontinued secukinumab vs.17·8% in the adalimumab group. This prespecified analysis in PsA patients with concomitant moderate to severe plaque psoriasis in the EXCEED study provides further evidence that IL-17 inhibitors offer a comprehensive biological treatment to manage the concomitant features of psoriasis and PsA.
Like
Save
Share